Com­ing up be­hind the mR­NA lead­ers, Sanofi, GSK piv­ot in­to PhI/II tri­al for their tra­di­tion­al tech ap­proach to a Covid-19 vac­cine. This race is­n't over yet

Right now all eyes are on a pair of cut­ting-edge mR­NA vac­cines cur­rent­ly cruis­ing through fast Phase III Covid-19 tri­als with a shot at de­liv­er­ing piv­otal, and like­ly quite con­tro­ver­sial, da­ta in Oc­to­ber. But as promised, Sanofi and GSK — with a big as­sist from the US gov­ern­ment — are launch­ing a Phase I/II study for an­oth­er vac­cine that re­lies on some re­as­sur­ing­ly tried-and-true tech­nol­o­gy on dis­play in the an­nu­al flu shot.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER